摘要
NAD(P)H:醌氧化还原酶1(NQO1)是一种抗氧化和解毒酶参与多种醌类的两电子还原。作为一种非酶基团,它参与多种肿瘤抑制基因如p53,p33和 p73α蛋白的稳定。醌氧化还原酶1在几种类型的肿瘤中高表达,与两种常见的基因多态性与癌症风险增加有关,使醌氧化还原酶1作为癌症新的治疗方法的一个潜在靶点。在这里,我们总结了醌氧化还原酶1的结构和酶学性质,以及其在肿瘤发生、发展和治疗中的作用。特别是,我们对最近的事态发展专注于在癌症相关的基因多态性功能的损失的分子基础的理解,并提出了新的方法来针对这些分子的缺陷,开发新的药物来拯救他们。我们将专注于药物治疗的目的是纠正蛋白质多态性的异常特性(如蛋白的稳定性和动力学)和调制导致丧失功能的细胞因子(如加速蛋白酶体降解)。
关键词: 癌,多态性,NAD(P)H:醌氧化还原酶1,药物分子伴侣,蛋白质动力学,蛋白酶体降解。
图形摘要
Current Drug Targets
Title:Natural Small Molecules as Stabilizers and Activators of Cancer-Associated NQO1 Polymorphisms
Volume: 17 Issue: 13
Author(s): Angel L. Pey, Clare F. Megarity, Encarnación Medina-Carmona, David J. Timson
Affiliation:
关键词: 癌,多态性,NAD(P)H:醌氧化还原酶1,药物分子伴侣,蛋白质动力学,蛋白酶体降解。
摘要: NAD(P)H: quinone oxidoreductase 1 (NQO1) is an antioxidant and detoxifying enzyme involved in the two-electron reduction of a wide variety of quinones. As a non-enzymatic function, it is involved in the stabilization of several tumour suppressors such as p53, p33 and p73α. NQO1 is overexpressed in several types of tumours, and two common polymorphisms are associated with increased cancer risk, making NQO1 a potential target for new cancer treatments. Here we review the structural and enzymological properties of NQO1, as well as its roles in cancer development and treatment. Particularly, we focus on recent developments on the understanding of the molecular basis leading to loss-of-function in cancer-associated polymorphisms, and propose new approaches to target these molecular defects to develop new pharmacological agents to rescue them. We will focus on pharmacological therapies aimed at correcting the abnormal properties of polymorphic proteins (such as protein stability and dynamics) and modulating intracellular factors leading to loss-of-function (such as accelerated proteasomal degradation).
Export Options
About this article
Cite this article as:
Angel L. Pey, Clare F. Megarity, Encarnación Medina-Carmona, David J. Timson , Natural Small Molecules as Stabilizers and Activators of Cancer-Associated NQO1 Polymorphisms, Current Drug Targets 2016; 17 (13) . https://dx.doi.org/10.2174/1389450117666160101121610
DOI https://dx.doi.org/10.2174/1389450117666160101121610 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
FOXO and FOXM1 in Cancer: The FOXO-FOXM1 Axis Shapes the Outcome of Cancer Chemotherapy
Current Drug Targets Cytochromes P450 in Brain: Function and Significance
Current Drug Metabolism Anti-cancer Nitrogen-Containing Heterocyclic Compounds
Current Organic Chemistry Current Status of SUMOylation Inhibitors
Current Medicinal Chemistry EGFR and the Complexity of Receptor Crosstalk in the Cardiovascular System
Current Molecular Medicine When BMP Signalling Goes Wrong: The Intracellular and Molecular Mechanisms of BMP Signalling in Cancer
Current Signal Transduction Therapy Insights into the Role of Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Health and Disease
Current Chemical Biology Improved Anti-Tumor Activity of Novel Highly Bioactive Liposome-Bound TRAIL in Breast Cancer Cells
Recent Patents on Anti-Cancer Drug Discovery Development of Liposomes and Pseudovirions with Fusion Activity for Efficient Gene Delivery
Current Gene Therapy Emerging Strategies to Strengthen the Anti-Tumour Activity of Type I Interferons: Overcoming Survival Pathways
Current Cancer Drug Targets Extranuclear Effects of Thyroid Hormones in Skeletal Muscle
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Hedgehog Signaling in the Normal and Neoplastic Mammary Gland
Current Drug Targets Intraperitoneal Drug Therapy: An Advantage
Current Clinical Pharmacology Renin-Angiotensin-Aldosterone System: A Current Drug Target for the Management of Neuropathic Pain
Current Drug Targets Implications of Photophysical and Physicochemical Factors on Successful Application of Photodynamic Therapy
Current Pharmaceutical Design Heat Shock Proteins as Prognostic Markers of Cancer
Current Cancer Drug Targets Recombinant Snake Venom Cystatin Inhibits Tumor Angiogenesis in vitro and in vivo Associated with Downregulation of VEGF-A165, Flt-1 and bFGF
Anti-Cancer Agents in Medicinal Chemistry Regulation of ABC Transporter Function Via Phosphorylation by Protein Kinases
Current Pharmaceutical Biotechnology Relaxin-Like Peptides in Neoplastic Lesions
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Resveratrol in Medicinal Chemistry: A Critical Review of its Pharmacokinetics, Drug-Delivery, and Membrane Interactions
Current Medicinal Chemistry